MedPath

Arvid Carlsson Research AB

🇸🇪Sweden
Ownership
-
Employees
-
Market Cap
-
Website

Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke

Phase 2
Completed
Conditions
Stroke Sequelae
Interventions
Drug: Placebo oral tablet
First Posted Date
2019-10-15
Last Posted Date
2020-10-01
Lead Sponsor
Arvid Carlsson Research AB
Target Recruit Count
101
Registration Number
NCT04127669
Locations
🇸🇪

Gottfries Clinic AB, Gothenburg, Sweden

© Copyright 2025. All Rights Reserved by MedPath